Safety and antisorptive power of Ibandronate applied in the real-life setting.
This study involved 78 participants taking 150 mg of Ibandronate once a month for the investigation of the drug efficacy and safety. Ibandronate had a strong antiresorptive action that decreased 67.9 per cent of bone resorption. The total cases of unwanted effect were 21 that showed the common adverse events like other bisphosphonate. The most common events were flu-like symptom (8.75%) and dyspepsia (7.5%) which occurred at the first tablet. Most participants subsided after the following months, but only one case persisted in these symptoms through the study period while the others had a myalgia, diarrhea and burning of epigastric in percent of 6.25, 2.5, 1.25 respectively. Ibandronate (150 mg) showed the strong antiresorptive effect and good compliance for taking once a month.
Bunyaratavej
Narong
N
Department of Orthopedic Surgery, Siriraj Hospital, Bangkok, Thailand. todrnarong@yahoo.com
Wajanavisit
Wiwat
W
Pauvilai
Prayook
P
Kitumnuoypong
Tassanee
T
Kittimanon
Nipat
N
Lektrakoon
Songkiat
S
D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D013785:Thailand; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid